Search results
Showing 2501 to 2550 of 4091 results for patient
Brolucizumab for treating wet age-related macular degeneration (TA672)
Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
the form of randomised controlled trials. These should report details of patient selection, duration and timing of stimulation, and...
applicable) Patient selection should be done by clinicians experienced in managing Barrett's oesophagus. Further research should report...
procedures guidance page . Any explanatory notes(if applicable) Patient selection should be done by clinicians experienced in managing...
during the evaluation of these treatments. This was informed by input from patient organisation groups, our partners and international...
transplantation, plus consolidation and maintenance treatment in chemosensitive patients at first response or first relapse? Any...
meta-analysis to strengthen results. The methods used should be patient-focused and include patient input on priority...
explanatory notes(if applicable) Further research should include: • patient selection in terms of age, skeletal maturity, and site and...
This quality standard covers the investigation and recognition of suspected cancer, and referral to specialist cancer services for adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS124Show all sections
Sections for QS124
- List of quality statements
- Quality statement 1: Direct access to diagnostic tests
- Quality statement 2: Urgent direct access endoscopy for oesophageal or stomach cancer
- Quality statement 3: Testing for blood in faeces
- Quality statement 4: Encouraging attendance at cancer services
- Update information
- About this quality standard
trials and report details of patient selection, treatment protocols, and long-term safety and efficacy including...
Evidence-based recommendations on DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography.
Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (HTG438)
Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy.
Evidence-based recommendations on blinatumomab (Blincyto) with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia in adults.
However, no published evidence was found to show whether or not it improves patient-reported outcomes in relation to suboptimal...
non-invasive and so carries negligible risks to the patient. However, EUS carries a small but significant risk of patient...
preferably be randomised controlled trials. It should report details of patient selection (including cause of fever, severity of stroke...
psychological wellbeing- ability to carry out normal activities- patient experience and patient-reported outcome measures....
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.
Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)
This guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long-term complications and improving quality of life.
This quality standard covers care and support and services for children, young people and adults with a learning disability (or a learning disability and autism) and behaviour that challenges, and their families and carers. It describes high quality care in priority areas for improvement.
View quality statements for QS101Show all sections
Sections for QS101
- Quality statements
- Quality statement 1: Lead commissioner
- Quality statement 2: Annual health check
- Quality statement 3: Initial assessment of behaviour that challenges
- Quality statement 4: Named lead practitioner
- Quality statement 5: Involving families and carers
- Quality statement 6: Parent-training programmes
- Quality statement 7: Personalised daily activities
of care improves patient experience, aids clinical decision-making and could reduce hospital admissions. GPs' knowledge of...
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)
Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin for people with mild chronic hepatitis C.
best treatment for this condition. Optimising treatment can lead to better patient satisfaction and the avoidance of unnecessary...
to on-demand NCP intervention in terms of the important outcomes for the patient and duration of effect of the procedure. On-demand NCP...
Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults.
should include randomised controlled trials and should report details of:• patient selection, including the age at which ovarian tissue...
Evidence summaries: new medicines – Integrated process statement (PMG11)
This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs
implantation for advanced age-related macular degeneration (AMD) which patients may benefit and on safety and efficacy outcomes,...
Improving outcomes for people with skin tumours including melanoma (CSG8)
This guideline covers how healthcare services for people with skin cancers should be organised. It aims to improve diagnosis and care by recommending which healthcare professionals should be involved and at which stage.
The PLASMA system for transurethral resection and haemostasis of the prostate (HTG563)
Evidence-based recommendations on the PLASMA system for transurethral resection and haemostasis of the prostate.
prescribing Measuring the use of NICE guidance Into practice resources Patient decision aids Implementation help and advice Cost saving,...
with high confidence and the impact of this on work prioritisation and patient flow the technical failure and rejection rates of the...
This guideline covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date and babies born at term, up to 28 days after their birth. Parenteral nutrition is often needed by preterm babies, critically ill babies, and babies who need surgery.
This guideline covers using psychosocial interventions to treat adults and young people over 16 who have a problem with or are dependent on opioids, stimulants or cannabis. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.
treatment-related morbidity, health-related quality of life, patient satisfaction, patient preference and overall response...
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
NICE has developed a medtech innovation briefing (MIB) on Proov Confirm for ovulation confirmation .
using a validated tool, for example the LARS score, which is a validated patient-administered questionnaire.No comparative evidence on...
This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)
Evidence-based recommendations on carmustine implants (Gliadel) and temozolomide for treating newly diagnosed high-grade glioma in adults.
View recommendations for TA121Show all sections
adolescents and during pregnancy. The Committee supports enrolment of patients into the aHUS registry and the collection of...
treatment that might not benefit them. Therefore, the committee agreed that a patient-centred approach to referral is important, and...
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services.
Guide to the technology appraisal and highly specialised technologies appeal process (PMG41)
This guide outlines the appeal process for the technology appraisal and highly specialised technologies guidance. It sets out the process that NICE follows for appeals and provides guidance for those who wish to make an appeal or who are considering doing so
Question Risk of radiotherapy in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently...
specialist palliative care in cancer patients, which generally points to earlier referral leading to better...
an indication of likely response to such treatments, thereby informing patient choice and leading to clinically and cost-effective...
Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.
Targeted-release budesonide for treating primary IgA nephropathy (TA1128)
Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.